Welcome to our dedicated page for Prestige Consmr Healthcare news (Ticker: PBH), a resource for investors and traders seeking the latest updates and insights on Prestige Consmr Healthcare stock.
The PBH news page on Stock Titan tracks announcements and disclosures from Prestige Consumer Healthcare Inc., a consumer healthcare products company listed on the New York Stock Exchange. Prestige issues frequent press releases covering its over-the-counter (OTC) brand portfolio, financial performance and corporate activities across the U.S. and Canada, Australia, and certain other international markets.
Investors and observers can use this news feed to follow quarterly and annual earnings releases, where Prestige reports revenues, net income, earnings per share, free cash flow, leverage and segment results for its North American OTC Healthcare and International OTC Healthcare businesses. These updates often highlight category trends such as gastrointestinal, women’s health, cough and cold, and eye and ear care, as well as the performance of brands including Monistat®, Summer’s Eve®, Clear Eyes®, Dramamine®, Fleet®, Hydralyte® and others.
The PBH news stream also includes announcements about investor conference participation, such as presentations at consumer staples and consumer growth and e-commerce conferences, and notices of upcoming earnings calls with webcast details. Corporate actions and regulatory topics appear as well, including the voluntary recall by Medtech Products Inc., a Prestige company, of specific lots of Little Remedies® Honey Cough Syrup due to microbial contamination, and communications about strategic transactions like the planned acquisition of Pillar5 Pharma Inc., a sterile ophthalmic manufacturer and Clear Eyes® supplier.
By reviewing the PBH news page regularly, readers can see how Prestige describes its business priorities, category performance, capital allocation decisions such as share repurchases, and developments affecting its OTC healthcare brands and supply chain.
Prestige Consumer Healthcare Inc. (NYSE:PBH) is set to release its fiscal 2023 fourth quarter and year-end earnings on May 4, 2023, before market opening. The company will hold a conference call on the same day at 8:30 a.m. ET to discuss these results. Investors can access the live webcast through the company's Investor Relations page or register for a phone call. A replay of the call will be available for a week post-event. Prestige Consumer Healthcare offers a diverse range of consumer healthcare products including Monistat®, BC®, Dramamine®, and many others, serving markets across the U.S., Canada, Australia, and beyond.
Prestige Consumer Healthcare (PBH) reported Q3 fiscal 2023 revenues of $275.5 million, a 0.4% increase from the previous year, with 1.8% growth excluding currency effects. Net income rose to $52.0 million, yielding diluted EPS of $1.04, up 5.1%. For the first nine months, revenues reached $841.9 million, a 2.7% increase year-over-year. The International OTC segment saw record revenues, growing 15.0% to $38.6 million. Management anticipates fiscal 2023 revenues between $1,120 and $1,122 million, projecting over 3% growth.
Prestige Consumer Healthcare Inc. (NYSE:PBH) will participate in the 2023 ICR Conference, hosting a fireside chat on January 10, 2023, at 2:30 p.m. ET. Interested parties can access the live webcast through the company's website under the 'Investors' section. Prestige Consumer Healthcare distributes various well-known consumer healthcare products including Monistat®, Summer’s Eve®, and Dramamine®. The firm's diverse portfolio serves retail markets in the U.S., Canada, Australia, and other international locations.
Prestige Consumer Healthcare Inc. (NYSE:PBH) has announced that it will release its fiscal 2023 third quarter earnings on February 2, 2023, before the market opens. A conference call to discuss these results will take place at 8:30 a.m. ET on the same day. Investors can join the call via a live Internet webcast or by phone after registering. A replay of the call will be available for one week afterward. This earnings report is pivotal for stakeholders to gauge the company’s financial health and performance metrics.
Prestige Consumer Healthcare (NYSE:PBH) reported Q2 fiscal 2023 revenue of $289.3 million, a 4.7% increase over the previous year, and earnings per share (EPS) of $1.02, surpassing expectations. The company reduced its debt by $35 million, achieving a leverage ratio of 3.7x. For the first half of fiscal 2023, revenue reached $566.3 million, up 3.8%. The company reaffirmed its fiscal 2023 revenue outlook of $1,120 to $1,130 million and EPS guidance of $4.18 to $4.23, amidst ongoing supply chain challenges.
Prestige Consumer Healthcare (NYSE:PBH) announced its fiscal 2023 Q2 earnings release on November 3, 2022, prior to market opening. The company will conduct a conference call at 8:30 a.m. ET on the same day to discuss the earnings results. Investors can join the live webcast via the Investor Relations page on their website or register for phone participation to receive dial-in details. A replay of the conference call will be available for one week post-event.
Prestige Consumer Healthcare Inc. (NYSE:PBH) will present at the 2022 Barclays Global Consumer Staples Conference on September 8, 2022, at 12:45 p.m. ET. Interested parties can access a live webcast via the company's website in the 'Investors' section. For those unable to attend the live session, a replay will be available afterward.
Prestige Consumer Healthcare offers a diverse range of products including Monistat®, Summer’s Eve®, BC®, and many more, catering to consumers across the U.S., Canada, Australia, and other international markets.
Prestige Consumer Healthcare (NYSE: PBH) reported Q1 fiscal 2023 revenue of $277.1 million, marking a 2.9% increase year-over-year. Diluted EPS stood at $1.09, exceeding expectations, while net income reached $55.3 million. Cash flow from operations was $58.2 million, with free cash flow at $57.2 million. The company reaffirmed its fiscal 2023 revenue outlook of $1.12 to $1.13 billion and EPS guidance of $4.18 to $4.23. Strategic share repurchase actions and debt reduction were highlighted as key focuses amid a challenging operating environment.
Prestige Consumer Healthcare Inc. (NYSE:PBH) will release its fiscal 2023 Q1 earnings on August 4, 2022, before market opening. A conference call to discuss the results will follow at 8:30 a.m. ET, accessible via the company's website. Participants can join through phone by dialing U.S./Canada: 833-634-2598 or internationally: 412-902-4108. A replay will be available for a week post-call using conference ID 9498360. The company markets a wide range of consumer healthcare products across North America and internationally.
Prestige Consumer Healthcare (PBH) reported strong financial results for fiscal 2022, with Q4 revenue of $266.9 million (up 12.3%) and full-year revenue of $1,086.8 million (up 15.2%). Adjusted diluted EPS for the year was $4.06 (up 25.3%). The company generated $259.9 million in net cash from operations, with record free cash flow of $253.7 million. The board authorized a $50 million share repurchase program. For fiscal 2023, PBH forecasts revenues between $1,120 million to $1,130 million, expecting organic growth of 2% to 3%.